HC Wainwright Issues Optimistic Estimate for AKRO Earnings

Akero Therapeutics, Inc. (NASDAQ:AKRO) – Equities researchers at HC Wainwright lifted their Q1 2025 earnings estimates for Akero Therapeutics in a report released on Monday, March 3rd. HC Wainwright analyst E. Arce now expects that the company will post earnings per share of ($0.96) for the quarter, up from their previous forecast of ($1.16). HC Wainwright has a “Buy” rating and a $75.00 price objective on the stock. The consensus estimate for Akero Therapeutics’ current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics’ Q2 2025 earnings at ($1.00) EPS, Q3 2025 earnings at ($1.04) EPS, Q4 2025 earnings at ($1.08) EPS, FY2025 earnings at ($4.07) EPS, FY2026 earnings at ($4.55) EPS, FY2027 earnings at ($4.19) EPS, FY2028 earnings at ($2.95) EPS and FY2029 earnings at $2.67 EPS.

Other research analysts have also recently issued research reports about the stock. Morgan Stanley raised their price target on shares of Akero Therapeutics from $46.00 to $96.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. Citigroup raised their price target on shares of Akero Therapeutics from $65.00 to $80.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Canaccord Genuity Group raised their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a report on Tuesday, January 28th. Bank of America raised shares of Akero Therapeutics from a “neutral” rating to a “buy” rating and raised their target price for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. Finally, UBS Group raised their target price on shares of Akero Therapeutics from $42.00 to $109.00 and gave the stock a “buy” rating in a report on Friday, January 31st. Nine equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, Akero Therapeutics currently has an average rating of “Buy” and a consensus target price of $76.29.

Akero Therapeutics Trading Down 3.2 %

NASDAQ AKRO opened at $43.67 on Thursday. The company has a fifty day simple moving average of $40.21 and a two-hundred day simple moving average of $33.07. The stock has a market cap of $3.05 billion, a P/E ratio of -11.65 and a beta of -0.19. Akero Therapeutics has a 12-month low of $17.86 and a 12-month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

Akero Therapeutics (NASDAQ:AKRO) last posted its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.01).

Insider Activity at Akero Therapeutics

In related news, CFO William Richard White sold 2,817 shares of the firm’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $30.79, for a total transaction of $86,735.43. Following the sale, the chief financial officer now owns 38,335 shares in the company, valued at approximately $1,180,334.65. This trade represents a 6.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Jonathan Young sold 10,000 shares of the firm’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $28.03, for a total transaction of $280,300.00. Following the sale, the chief operating officer now owns 218,083 shares in the company, valued at approximately $6,112,866.49. This represents a 4.38 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 224,992 shares of company stock worth $10,800,953. 7.94% of the stock is owned by company insiders.

Institutional Trading of Akero Therapeutics

Several institutional investors have recently modified their holdings of AKRO. Wellington Management Group LLP grew its position in shares of Akero Therapeutics by 54.4% in the third quarter. Wellington Management Group LLP now owns 7,896,632 shares of the company’s stock valued at $226,554,000 after purchasing an additional 2,782,029 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Akero Therapeutics in the third quarter valued at about $37,392,000. RTW Investments LP grew its position in shares of Akero Therapeutics by 15.9% in the fourth quarter. RTW Investments LP now owns 6,859,823 shares of the company’s stock valued at $190,840,000 after purchasing an additional 940,388 shares during the period. Deep Track Capital LP grew its position in shares of Akero Therapeutics by 116.0% in the fourth quarter. Deep Track Capital LP now owns 1,490,000 shares of the company’s stock valued at $41,452,000 after purchasing an additional 800,216 shares during the period. Finally, Balyasny Asset Management L.P. acquired a new stake in shares of Akero Therapeutics in the fourth quarter valued at about $18,059,000.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.